New HoFH drug, KYNAMRO, approved by the FDA

No Comments

On January 29th, 2013, Genzyme (a Sanofi company), and Isis Pharmaceuticals Inc. announced that after two years of patient clinical trials the US Food and Drug Administration has approved Kynamro ™ (generic name: mipomersen sodium) for the treatment of Homozygous Familial Hypercholesterolemia, the … Read More

FDA Approves New Treatment for HoFH

No Comments

On Dec 24th, 2012 Aegerion Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) approved new treatment for Homozygous Familial Hypercholesterolemia (HoFH) called JUXTAPID™ (lomitapide). The capsules are intended as an adjunct to a low-fat diet and other cholesterol-lowering … Read More

Learn About Cascade Screening and FH


In September, the FH Foundation participated in the “New Strategies in Public Health Genomics” conference at the Centers for Disease Control (CDC).  Experts and key stakeholders, including advocates, community leaders and clinicians, came together to discuss evidence-based genomic programs … Read More